Black Rock Inc. Vaxart, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Vaxart, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,774,346 shares of VXRT stock, worth $674,251. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,774,346

Previous 1,774,346 -0.0%

Holding current value

$674,251

Previous $2.31 Million 48.48%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.56 - $1.41 $8,466 - $21,316	-15,118 Reduced 0.84%	1,774,346 $2.31 Million
Q3 2023 Nov 13, 2023	SELL	$0.69 - $0.85 $96,079 - $118,358	-139,245 Reduced 7.22%	1,789,464 $1.34 Million
Q2 2023 Aug 11, 2023	SELL	$0.6 - $1.41 $4.13 Million - $9.71 Million	-6,889,938 Reduced 78.13%	1,928,709 $1.41 Million
Q1 2023 May 12, 2023	SELL	$0.71 - $1.25 $28,100 - $49,472	-39,578 Reduced 0.45%	8,818,647 $6.7 Million
Q4 2022 Feb 13, 2023	SELL	$0.75 - $2.24 $191,085 - $570,707	-254,780 Reduced 2.8%	8,858,225 $8.5 Million
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $148,866 - $320,526	-71,228 Reduced 0.78%	9,113,005 $19.9 Million
Q2 2022 Aug 12, 2022	BUY	$2.7 - $5.28 $2 Million - $3.92 Million	741,604 Added 8.78%	9,184,233 $32.1 Million
Q1 2022 May 12, 2022	SELL	$4.29 - $6.64 $42,003 - $65,012	-9,791 Reduced 0.12%	8,442,629 $42.6 Million
Q4 2021 Feb 10, 2022	BUY	$5.77 - $7.96 $2.06 Million - $2.84 Million	357,036 Added 4.41%	8,452,420 $53 Million
Q3 2021 Nov 09, 2021	SELL	$6.67 - $9.8 $492,172 - $723,132	-73,789 Reduced 0.9%	8,095,384 $64.4 Million
Q2 2021 Aug 11, 2021	BUY	$5.06 - $10.78 $41.3 Million - $88.1 Million	8,169,173 New	8,169,173 $61.2 Million

Others Institutions Holding VXRT

# of Institutions

106

Shares Held

23.1M

Call Options Held

66.1K

Put Options Held

View Full List

About Vaxart, Inc.

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $48.1M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

More about VXRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account